Novartis to Buy U.S.-Based Chinook
Novartis has agreed to acquire Chinook Therapeutics for up to $3.5 billion, in a deal that will expand its portfolio of kidney disease treatments.
Novartis has agreed to acquire Chinook Therapeutics for up to $3.5 billion, in a deal that will expand its portfolio of kidney disease treatments.
What's Your Reaction?